Something unexpected was hiding in the chemical signature of tumors: hints of diet, tobacco, education and even a decades-old herbicide. Short marks on the genome—epigenetic post-its—are starting to read like a life story, and that story may help explain why colorectal cancer is climbing among people under 50.
Researchers at the Vall d’Hebron Institute of Oncology (VHIO), led by José A. Seoane, followed those marks—specifically DNA methylation patterns—to trace the “exposome,” the sum of environmental and lifestyle exposures across a lifetime. Their work, published in Nature Medicine on 21 April 2026, compared methylation fingerprints from patients diagnosed before and after age 50 and found persistent differences that point to real-world exposures rather than new inherited genes.
Think of the genome as a library. The text doesn’t change. What changes are the sticky notes that decide which shelves get pulled down. Epigenetic marks attach and detach depending on what a person eats, what they inhale, where they live and other daily realities. Seoane and colleagues used those marks to assemble exposure scores and then tested them across multiple data sets to see whether early-onset and late-onset colorectal cancers carry different exposure histories.
Methodologically it was careful and broad. The team trained methylation-based exposure scores using TCGA data, then validated results in nine independent cohorts. That cross-checking reduced the chance that the signals were random. The outcome: epigenetic signals tied to diet and smoking showed up more often in early-onset cases, and a striking association with the herbicide picloram emerged.
Picloram isn’t new. It’s been used on farms since the 1960s. But timing matters. People diagnosed with colorectal cancer after age 50 likely spent childhood in an era before widespread picloram use; those diagnosed earlier may have experienced exposure over a larger portion of their lives. To probe the link further, the team combined tumor methylation data with population-level registries—the US NCI SEER cancer registries—and county-level pesticide application records from the USGS. The association with picloram remained significant even after accounting for sociodemographic variables and other chemicals.
Even more intriguing was what the tumors themselves revealed. High predicted picloram exposure correlated with cancers that carried fewer mutations in the APC gene, a classic driver of colorectal tumorigenesis through the Wnt signaling pathway. In plain terms, this suggests that some environmental exposures might nudge tissues down an alternate route toward malignancy—one that doesn’t rely on the textbook APC mutation pattern.
These findings don’t rewrite cause and effect overnight. Association is not proof. Yet the study shows methylation as a practical tool to ‘‘read’’ accumulated exposures in tissue, offering a bridge between messy lifetime histories and measurable molecular change. For clinicians and public-health planners, that bridge matters: it points toward modifiable risks and policy levers rather than fatalistic genetic explanations.
Prevention, then, shifts outward from the nucleus to the neighborhood and the dinner plate. Reducing tobacco use, improving diets, and scrutinizing long-standing pesticide practices may all be pieces of a strategy to slow the rise of early-onset colorectal cancer. The work from VHIO opens a new forensic angle on a troubling trend—one that demands follow-up studies, regulatory attention and, perhaps, a different way of thinking about how environment and epigenetics conspire to shape cancer risk.
If we can read the post-its on our genome, the question becomes: will we change the notes we leave behind?
Leave a Comment
Comments
No comments yet. Be the first.